Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Qiagen shares jump on renewed takeover speculation

share with twitter share with LinkedIn share with facebook
share via e-mail
01/20/2020 | 03:25am EST

Shares in genetic testing company Qiagen rose 3.6% on Monday after a report that the firm was talking to an interested party about a possible acquisition.

On Friday, the CTFN website cited an unnamed industry executive as saying Qiagen was in talks about a possible takeover.

A Qiagen spokesman declined to comment on the report.

In December, shares in Qiagen plunged after the company said it had decided against a sale as it saw continuing to be a stand-alone business as the best option, terminating all discussions and saying they were not compelling.

(Reporting by Emma Thomasson; Editing by Riham Alkousaa)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN N.V.
02/19QIAGEN : 's QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nig..
BU
02/04Qiagen beats fourth quarter growth consensus after streamlining operations
RE
02/04QIAGEN : 4Q Earnings Snapshot
AQ
02/04QIAGEN : Reports Results for Fourth Quarter and Full-Year 2019
BU
02/04QIAGEN : Annual results
CO
02/03QIAGEN : Launches FFPE and Liquid Biopsy PIK3CA Diagnostics in Europe to Enhance..
BU
01/24QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
01/21QIAGEN : Digital Insights Publication Roundup (Winter 2019/2020)
AQ
01/20Qiagen shares jump on renewed takeover speculation
RE
01/17QIAGEN N.V. : Crossing thresholds
CO
More news
Financials (USD)
Sales 2020 1 573 M
EBIT 2020 447 M
Net income 2020 236 M
Debt 2020 826 M
Yield 2020 -
P/E ratio 2020 35,3x
P/E ratio 2021 30,2x
EV / Sales2020 5,93x
EV / Sales2021 5,34x
Capitalization 8 497 M
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 35,59  $
Last Close Price 37,31  $
Spread / Highest target 15,3%
Spread / Average Target -4,60%
Spread / Lowest Target -16,9%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Elizabeth E. Tallett Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.10.38%8 497
LONZA GROUP19.03%31 732
IQVIA HOLDINGS INC.6.23%31 649
SEATTLE GENETICS, INC.3.56%20 383
CELLTRION, INC.--.--%19 812
INCYTE CORPORATION-5.61%17 943